Document is current

Any future updates will be listed below

Cost-effectiveness of sacituzumab govitecan for hormone receptor-positive human epidermal growth factor receptor 2-negative metastatic breast cancer based on the EVER-132-002 trial in China

Crossref DOI link: https://doi.org/10.1186/s12962-025-00613-z

Published Online: 2025-03-19

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark